Yoshiyasu Karino

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda et al. · Hepatology · 2014 · 539 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Clinical features of hepatocellular carcinoma with extrahepatic metastases

Mitsuteru Natsuizaka, Takumi Omura, Toru Akaike et al. · Journal of Gastroenterology and Hepatology · 2005 · 533 citations

Medicine, Oncology, Surgery +14

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota et al. · Hepatology · 2011 · 335 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki et al. · Journal of Hepatology · 2012 · 236 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14